Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Greater China, to Taiwan’s LaunXP Biomedical ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...

Cologuard is getting an upgrade after 10 years on the market, as Exact Sciences starts to roll out the new version of its ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests ...

Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases ...